Feasibility of neoadjuvant therapy in resectable biliary adenocarcinoma.
This trial will evaluate whether a neoadjuvant paradigm is feasible in resectable biliary adenocarcinoma. All components of therapy are currently used standards of care, however they have not been used in the neoadjuvant setting for the management of resectable biliary cancers. The study will use Gemcitabine/cisplatin, followed by chemoradiation.
This is a feasibility trial with an accrual goal of 12 patients using the primary endpoint of completion of neoadjuvant therapy and surgery as an assessment of feasibility.
| Condition | Adenocarcinoma, Malignant Adenoma, Adenocarcinoma, Cholangiocarcinoma, Biliary neoplasm, Biliary Tract Cancer, Urothelial Tract Cancer, Urothelial Tract Cancer, Malignant Adenoma, Biliary Tract Cancer, biliary cancer |
|---|---|
| Treatment | fluorouracil, cisplatin, Gemcitabine, Short course ChemoRT |
| Clinical Study Identifier | NCT04480190 |
| Sponsor | Jordan Kharofa |
| Last Modified on | 28 April 2022 |
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer
Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!
No annotations made yet
Congrats! You have your own personal workspace now.